Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) --  Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Chimerix, Inc. (NASDAQ: CMRX), to acquire Chimerix's exclusive worldwide rights to TEMBEXA® (brincidofovir), the first antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

Jack in the Box

Monro

Patrick Industries

Shutterstock

Ultra Clean

Xencor

Many small-cap stocks in the S&P 600 Small Cap Index aren't big names, but they have the change of bringing big rewards. The post 7 High-Risk, High-Reward Small-Cap Stocks to Buy Now appeared first on InvestorPlace.

7 High-Risk, High-Reward Small-Cap Stocks to Buy Now

GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT.

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT

NEW YORK , May 10, 2022 /PRNewswire/ -- Weiss Law, a national shareholders' rights law firm, is investigating possible false claims, deceptive accounting and reporting practices, breaches of fiduciary duty, and violations of the federal securities laws by the Board of Directors and certain Company officers of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent" or the "Company"). According to a final report expected to be released today after a year-long investigation by the House of Representatives' Select Subcommittee on the Coronavirus Crisis, the Company, hired to produce hundreds of millions of coronavirus vaccine doses, hid from US Food and Drug Administration ("FDA") inspectors evidence of quality control problems in February 2021- six weeks before it alerted federal officials that 15 million doses were contaminated.

SHAREHOLDER ALERT: Weiss Law Investigates Emergent BioSolutions Inc.

Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.

Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates

Emergent BioSolutions Inc (NYSE: EBS) reported Q1 sales of $307.5 million, down 10% Y/Y, beating the consensus of $283 million. Total product sales increased 72% to $237.1 million, while Contract development & manufacturing (CDMO) revenues declined 67% to $60.8 million.

Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements

Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2022 Results Conference Call April 28, 2022 5:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Rich Lindahl - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Lisa Springer - Singular Research Operator Good day, and thank you for standing by. Welcome to the First Quarter 2022 Emergent BioSolutions Earnings Conference Call.

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q1 2022 Results - Earnings Call Transcript

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25% and 3.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Q1 Earnings Lag Estimates

GAITHERSBURG, Md., April 28, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2022.

Emergent BioSolutions Reports Financial Results For First Quarter 2022

Gilead Sciences

Eli Lilly

Merck

Sanofi

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

In early 2021, in the eye of the Covid storm, there was a mix-up in the manufacturing of the Covid-19 vaccine developed by Johnson & Johnson ( JNJ , Financial) and manufactured by the contractor Emergent BioSolutions Inc. ( EBS , Financial). At Emergent's Bayview site in Maryland, where the AstraZeneca ( AZN , Financial) Covid vaccine was also manufactured, workers had accidentally mixed up ingredients of the two vaccines.

Emergent Biosolutions - Still in the Doghouse

GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the second quarter of 2022, and financial outlook for full year 2022.

Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022

GAITHERSBURG, Md., March 23, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its board of directors (the “board”) has undertaken a series of changes consistent with its commitment to continuous improvement of best practices for corporate governance.

Emergent BioSolutions Provides Corporate Governance Update

Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.

Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study

GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a treatment being developed for known or suspected acute cyanide poisoning. Under an existing multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), and in collaboration with the Southwest Research Institute, Emergent is developing a single-use intranasal spray intended for administration by first responders and medical personnel following a cyanide incident.

Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning

There's considerable uncertainty about the company's near-term prospects.

Emergent BioSolutions Stock Fell Today -- Is It a Buy?

Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.

Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut

The company disappointed investors with its 2022 guidance.

Why Emergent BioSciences Stock Is Slipping Today

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2021 Results - Earnings Call Transcript

ACADIA Pharma

While the theme underperformed considerably in 2021, declining by 31%, it has gained about 2% year-to-date in 2022, outperforming the S&P 500, which remains down by about 9%.

These Healthcare Stocks Took A Beating Through Covid. Will They Outperform In 2022?

Aerie Pharmaceuticals

Editas Medicine

Moderna

Vir Biotechnology

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Emergent BioSolutions has been an exiled ticker following the vaccine mix-up at the company's Bayview Facility last year. Although the company has addressed the issues in Bayview, it looks as if the market has expelled EBS as a good investment at this point in time.

Emergent BioSolutions: Still A Bargain Regardless Of Diminished Growth Forecasts

GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial outlook for full year 2022, and revenue guidance for the first quarter of 2022.

Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022

Cavco Industries

Ingevity

TechTarget

The S&P 500 saw the trailing 12-month real earnings per share of its member companies increase by a compound annual growth rate of 11.6% over the past five years. The index, which stood at a price of $4,500.53 per share as of Friday, has climbed more than 95% over the past five years.

4 Companies Growing Earnings Fast

Fuad El-Hibri to Retire After More Than 20 Years Fuad El-Hibri to Retire After More Than 20 Years

News for Emergent BioSolutions Stock (EBS)